Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

On August 17, 2022 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported that it has observed a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial (Press release, Scandion Oncology, AUG 17, 2022, View Source,c3615032 [SID1234618452]). Thus, dosing is now escalated to higher levels than expected based on the initial findings in the CORIST trial, which prompted the amendment of the PANTAX trial design communicated in January 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The continued dose escalation extends the PANTAX trial meaning it is now expected to read out in the first half of 2023 (previously expected in the third quarter of 2022). Trial execution is strong with good patient recruitment and the trial is progressing well.

PANTAX is a dose-finding phase Ib-trial in patients with unresectable or metastatic pancreatic

cancer who are offered SCO-101 as an add-on therapy to their standard chemotherapy. The good tolerability of SCO-101 observed in this setting supports the overall profile of the compound as well tolerated in vulnerable patients.

"We have been positively surprised by the tolerability of SCO-101 observed in this trial, which further supports our belief in the potential of SCO-101 as a new cancer treatment improving options for patients. Naturally, we continue the dose escalation beyond our expectations in order to find the optimal dose of SCO-101 in this indication and combination, even if this of course postpones the readout from the trial", says Bo Rode Hansen, President & CEO of Scandion.

Scandion is also currently carrying out the CORIST phase 2-trial in which SCO-101 is studied as combination therapy in patients with metastatic colorectal cancer. Topline data from the ongoing second part of this trial is still expected during the third quarter of 2022.